International breakthrough for Jyväskylä-based Wellpro – cooperation with global pharmaceutical giant
begins
Wellpro Impact Solutions Oy has signed a two-year cooperation agreement
with global pharmaceutical giant Boehringer Ingelheim. The agreement concerns
the implementation of digital BitHabit tools in the
impact-based health programme in the North Savo Wellbeing Region, which is developing the treatment of type 2 diabetes (T2D).
Boehringer Ingelheim is one of the world’s largest and longest-standing family-owned pharmaceutical
companies.
This is a major international head start for the Jyväskylä-based
wellbeing technology company.
A major step forward for Finnish health technology
The BitHabit app can be used to treat lifestyle diseases such as type 2 diabetes, obesity and reduce risks to brain and memory health. BitHabit is an app developed in Finland based on the impact of small lifestyle changes on human well-being. The app was developed in a 6-year national project to study the effectiveness of small lifestyle changes. The research was carried out by THL, the University of Eastern Finland and VTT. The study has been published in several medical journals. Wellpro Impact Solutions Ltd has continued the development of the application from 2022 onwards.
In autumn 2025, a new user interface will be released, which will be available in app stores, as well as a virtual assistant that will improve the sensory experience.
Wellpro Impact Solutions Oy has signed a two-year cooperation agreement
with global pharmaceutical giant Boehringer Ingelheim. The agreement concerns
the implementation of digital BitHabit tools in the
impact-based health programme in the North Savo wellbeing area, which is developing the treatment of type 2 diabetes (T2D).
Boehringer Ingelheim is one of the world’s largest and longest-standing family-owned pharmaceutical
companies.
This is a major international head start for the Jyväskylä-based
wellbeing technology company. “This is an important step for us, above all from the point of view of
impact. We have developed BitHabit to give everyone the opportunity to improve
their well-being with small, scientifically proven actions,” says Petteri Sveins, CEO of Wellpro.
BitHabit – the interface to a better life
BitHabit is a science-based digital lifestyle prevention tool that brings support
and information to the user’s everyday life – directly to the smartphone. BitHabit provides users with concrete,
personalised ways to support medication management, prevent disease worsening and improve
quality of life.
“The lessons learned from this health programme on the treatment of type 2 diabetes can be widely used in the future
to treat other lifestyle diseases such as cardiovascular diseases,
memory disorders or obesity. My vision and vision is that every time a person
receives a prescription for, for example, a blood pressure, cholesterol or weight management medicine,
a QR code could be included in the medicine package, giving the patient access to a digital
tool to support their well-being. In this way, the medicine is accompanied by a concrete
opportunity to make a difference to their health – one small action at a time.” says Petteri Sveins.
An export of well-being from Finland to the world
The cooperation agreement with Boehringer Ingelheim is just the beginning. Negotiations for international
expansion are already underway. Boehringer has operations in more than 130 countries, and a common
goal with Wellpro is to develop and scale good treatment practices to global markets.
BitHabit is not a medical device, but a health-promoting mobile wellness tool
. It is not a substitute for medicines, but it supports their effectiveness and above all helps
people to take concrete steps towards a healthier everyday life.
Type 2 diabetes treatment takes the next step
The North Savo Wellbeing Region and the Diabetes Association are collaborating on a T2D care development project based on
effectiveness, with BitHabit as a key tool. The number of people with type
2 diabetes is increasing in Finland and internationally, and new solutions are needed to
develop treatment. The University of Eastern Finland is responsible for the scientific
research of the project. The aim of the programme is to develop an impact investment model (SIB)
for the period 2026-2027 with the aim of developing effective and cost-efficient approaches
that improve the quality and effectiveness of diabetes care and reduce the incidence of additional
diseases. According to the National Diabetes Quality Register, the balance of diabetes care has already
improved in Northern Savo, especially for bad cholesterol.
BitHabit -
Five (5) simple ways to feel better - start today
